Article
Surgery
Yuping Tan, Biao Yang, Yuhong Chen, Xi Yan
Summary: This study compares the survival outcomes of metaplastic breast cancer (MPBC) with triple-negative breast cancer (TNBC) and identifies prognostic factors for both types of cancer. The study finds that MPBC is associated with worse overall survival (OS) and disease-free survival (DFS) compared to TNBC. Additionally, within the MPBC group, the subtype with mesenchymal differentiation has a worse DFS compared to other subtypes.
WORLD JOURNAL OF SURGERY
(2023)
Article
Endocrinology & Metabolism
Jinqian Mao, Jin Hu, Yanting Zhang, Jian Shen, Fang Dong, Ximeng Zhang, Jie Ming, Tao Huang, Xiaoqin Run
Summary: This study compared single hormone receptor-positive breast cancer to other subtypes and found clinically and biologically distinct features. The prognosis of single hormone receptor-positive tumors was similar to hormone receptor-negative and hormone receptor-positive tumors in patients with or without HER2 overexpression.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Yuki Eguchi, Tokiko Nakai, Motohiro Kojima, Masashi Wakabayashi, Naoya Sakamoto, Shingo Sakashita, Saori Miyazaki, Tetsuro Taki, Reiko Watanabe, Rurina Watanuki, Chisako Yamauchi, Tsuguo Iwatani, Toru Mukohara, Tatsuya Onishi, Genichiro Ishii
Summary: This study evaluated the usefulness of residual tumor area (ART) as a method for predicting the prognosis of triple-negative breast cancer (TNBC) patients after neoadjuvant chemotherapy (NAC). The results showed that patients in the ART-high group had significantly shorter recurrence-free survival (RFS) and overall survival (OS) compared to the ART-0 and ART-low groups. ART-0 and ART-low, as well as ypN(-), were identified as independent favorable prognostic factors for RFS. Patients with low ART and ypN(-) or no residual tumor (ART-0) showed better prognosis.
Article
Oncology
Pooja Srivastava, Tiannan Wang, Beth Z. Clark, Jing Yu, Jeffrey L. Fine, Tatiana M. Villatoro, Gloria J. Carter, Adam M. Brufsky, Vikram C. Gorantla, Shannon L. Huggins-Puhalla, Leisha A. Emens, Thais Basili, Edaise M. da Silva, Jorge S. Reis-Filho, Rohit Bhargava
Summary: Triple-negative breast cancers with low proliferation are rare and mainly consist of low to intermediate-grade pure apocrine or apocrine differentiated tumors. For stage-I low proliferation TNBC, de-escalation of chemotherapy may be considered due to the overall good prognosis and limited benefits of chemotherapy.
Article
Multidisciplinary Sciences
Zijian Zhou, Beatriz E. Adrada, Rosalind P. Candelaria, Nabil A. Elshafeey, Medine Boge, Rania M. Mohamed, Sanaz Pashapoor, Jia Sun, Zhan Xu, Bikash Panthi, Jong Bum Son, Mary S. Guirguis, Miral M. Patel, Gary J. Whitman, Tanya W. Moseley, Marion E. Scoggins, Jason B. White, Jennifer K. Litton, Vicente Valero, Kelly K. Hunt, Debu Tripathy, Wei Yang, Peng Wei, Clinton Yam, Mark D. Pagel, Gaiane M. Rauch, Jingfei Ma
Summary: Deep learning based on multiparametric MRI can potentially predict TNBC patients' pCR status in the breast early during NAST.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Keying Zhu, Yuyuan Chen, Rong Guo, Lanyi Dai, Jiankui Wang, Yiyin Tang, Shaoqiang Zhou, Dedian Chen, Sheng Huang
Summary: This study constructed a diagnostic model based on a parametric survival model from the SEER database, which can accurately predict the prognosis of patients with TN MpBC after surgery. The generated diagnostic tool based on this model demonstrated clinical applicability and can help improve patient care.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Grazia Vernaci, Edoardo Vincenzo Savarino, Ilaria Patuzzi, Sonia Facchin, Fabiana Zingone, Davide Massa, Giovanni Faggioni, Tommaso Giarratano, Federica Miglietta, Gaia Griguolo, Matteo Fassan, Marcello Lo Mele, Elisa Gasparini, Giancarlo Bisagni, Valentina Guarneri, Maria Vittoria Dieci
Summary: This article evaluates the feasibility of analyzing the gut microbiome in patients with early stage triple-negative breast cancer (TNBC) undergoing neoadjuvant chemotherapy, and explores its impact on treatment response and clinicopathologic factors. The study suggests that analyzing the gut microbiome may have potential significance in early TNBC, but further investigation is needed to understand its complex correlation with immunity and cancer.
Review
Oncology
Filippo Borri, Annarita Granaglia
Summary: This review discusses the pathological aspects, molecular markers, and new frontier of immunotherapy in triple-negative breast cancer (TNBC), emphasizing the importance of histological diagnosis on clinical outcomes.
SEMINARS IN CANCER BIOLOGY
(2021)
Article
Oncology
Clinton Yam, Er-Yen Yen, Jeffrey T. Chang, Roland L. Bassett, Gheath Alatrash, Haven Garber, Lei Huo, Fei Yang, Anne Philips, Qing-Qing Ding, Bora Lim, Naoto T. Ueno, Kasthuri Kannan, Xiangjie Sun, Baohua Sun, Edwin Roger Parra Cuentas, William Fraser Symmans, Jason B. White, Elizabeth Ravenberg, Sahil Seth, Jennifer L. Guerriero, Gaiane M. Rauch, Senthil Damodaran, Jennifer K. Litton, Jennifer A. Wargo, Gabriel N. Hortobagyi, Andrew Futreal, Ignacio I. Wistuba, Ryan Sun, Stacy L. Moulder, Elizabeth A. Mittendorf
Summary: The study found that in patients with triple-negative breast cancer receiving neoadjuvant therapy, TCR clonality, PD-L1 positivity, CD3(+):CD68(+) ratio, and spatial proximity of T cells to tumor cells were associated with pathologic complete response. Deep immune profiling through detailed phenotypic characterization and spatial analysis can improve prediction of pathologic complete response in these patients.
CLINICAL CANCER RESEARCH
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Toulsie Ramtohul, Clara Tescher, Pauline Vaflard, Joanna Cyrta, Noemie Girard, Caroline Malhaire, Anne Tardivon
Summary: The study aimed to evaluate whether semiquantitative perfusion parameters calculated at initial ultrafast DCE MRI can predict pathologic response after neoadjuvant chemotherapy in breast cancer patients. The results showed that the wash-in slope (WIS) parameter was an independent predictor associated with pathologic complete response, and it could differentiate subgroups of breast cancer patients with different rates of pathologic complete response.
Article
Biochemistry & Molecular Biology
Jean Ogier du Terrail, Armand Leopold, Clement Joly, Constance Beguier, Mathieu Andreux, Charles Maussion, Benoit Schmauch, Eric W. Tramel, Etienne Bendjebbar, Mikhail Zaslavskiy, Gilles Wainrib, Maud Milder, Julie Gervasoni, Julien Guerin, Thierry Durand, Alain Livartowski, Kelvin Moutet, Clement Gautier, Inal Djafar, Anne-Laure Moisson, Camille Marini, Mathieu Galtier, Felix Balazard, Remy Dubois, Jeverson Moreira, Antoine Simon, Damien Drubay, Magali Lacroix-Triki, Camille Franchet, Guillaume Bataillon, Pierre-Etienne Heudel
Summary: Triple-negative breast cancer (TNBC), a rare and aggressive form of breast cancer, has limited treatment options. In this study, machine learning was used to predict the response to neoadjuvant chemotherapy in early TNBC patients, using whole-slide images and clinical information. A multicentric TNBC study was conducted using federated learning to protect patient data privacy, and the results showed that collaborative training of machine learning models significantly improved prediction performance. This concept study highlights the potential of using federated learning with large datasets for biomarker discovery in TNBC.
Article
Oncology
Makoto Ishitobi, Naoko Matsuda, Mizuho Tazo, Sayuka Nakayama, Ryu Tokui, Tomoko Ogawa, Atsushi Yoshida, Yasuyuki Kojima, Takashi Kuwayama, Takahiro Nakayama, Hideko Yamauchi, Seigo Nakamura, Koichiro Tsugawa, Naoki Hayashi
Summary: This study investigated the risk factors for ipsilateral breast tumor recurrence (IBTR) among breast cancer patients with triple-negative or HER2+ tumors who achieved ypT0 after neoadjuvant chemotherapy (NAC) and breast-conserving treatment. The results showed that age at diagnosis was independently associated with IBTR-free survival, with younger patients having significantly worse prognosis.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Carlos H. Barrios, Shigehira Saji, Nadia Harbeck, Hong Zhang, Kyung H. Jung, Sheetal Patel, Shilpen Patel, Anh Nguyen Duc, Mario Liste-Hermoso, Stephen Y. Chui, Elizabeth A. Mittendorf
Summary: This study assessed patients' experience of treatment burden when adding atezolizumab to neoadjuvant chemotherapy for early-stage TNBC. The results showed that adding atezolizumab did not impose additional treatment burden on patients while improving pathologic complete response.
Article
Radiology, Nuclear Medicine & Medical Imaging
Romain-David Seban, Emilie Arnaud, Delphine Loirat, Luc Cabel, Paul Cottu, Lounes Djerroudi, Segolene Hescot, Pierre Loap, Claire Bonneau, Francois-Clement Bidard, Virginie Huchet, Nina Jehanno, Arnaud Berenbaum, Laurence Champion, Irene Buvat
Summary: This study retrospectively investigated whether [18F]FDG PET/CT examination before neoadjuvant chemotherapy could predict complete pathological complete response (pCR) in patients with early-stage triple-negative breast cancer (TNBC). The results showed that high tumor metabolism and low tumor burden could predict pCR after neoadjuvant chemotherapy.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Wei Zhang, Emma Li, Lily Wang, Brian D. D. Lehmann, X. Steven Chen
Summary: This study aimed to identify genes associated with neoadjuvant chemotherapy (NAC) response and disease-free survival (DFS) of triple-negative breast cancer (TNBC) patients. Large-scale meta-analyses were conducted to identify genes associated with NAC response and survival outcomes. The integration and division of gene associations provided insights into potential NAC response mechanisms and biomarker discovery.
Article
Multidisciplinary Sciences
Lucia Ruojia Wu, Peng Dai, Michael Xiangjiang Wang, Sherry Xi Chen, Evan N. Cohen, Gitanjali Jayachandran, Jinny Xuemeng Zhang, Angela Serrano, Nina Guanyi Xie, Naoto T. Ueno, James M. Reuben, Carlos H. Barcenas, David Yu Zhang
Summary: The authors report a PCR-based molecular barcoding sequencing method called quantitative amplicon sequencing (QASeq), which allows accurate and sensitive quantification of nucleic acids. Compared to traditional droplet digital PCR, QASeq exhibits higher and more consistent conversion yield in molecule count quantitation. Multiplexing with QASeq improves the sensitivity of detecting copy number variation (CNV).
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Nour Abuhadra, Ryan Sun, Jennifer K. Litton, Gaiane M. Rauch, Clinton Yam, Jeffrey T. Chang, Sahil Seth, Roland Bassett, Bora Lim, Alastair M. Thompson, Elizabeth Mittendorf, Beatriz E. Adrada, Senthil Damodaran, Jason White, Elizabeth Ravenberg, Rosalind Candelaria, Banu Arun, Naoto T. Ueno, Lumarie Santiago, Sadia Saleem, Sausan Abouharb, Rashmi K. Murthy, Nuhad Ibrahim, Aysegul A. Sahin, Vicente Valero, William Fraser Symmans, Debu Tripathy, Stacy Moulder, Lei Huo
Summary: In TNBC patients without a complete pathologic response, high baseline stromal tumor-infiltrating lymphocytes (sTILs) did not show a significant association with event-free survival (EFS), suggesting that sTILs may not confer a benefit in EFS in the absence of a pCR. RNA-seq analysis revealed more CD8+ T cells in the high-sTIL group with favorable EFS, indicating lymphocyte type may be an important parameter for de-escalation strategies. Further research is needed to investigate the implications of these findings in the context of immune checkpoint inhibitor therapy.
Article
Oncology
Maitri Kalra, Elizabeth Henry, Kelly McCann, Meghan S. Karuturi, Jean G. Bustamante Alvarez, Amanda Parkes, Robert Wesolowski, Mei Wei, Sarah S. Mougalian, Gregory Durm, Angel Qin, Caitlin Schonewolf, Meghna Trivedi, Avan J. Armaghani, Frederick H. Wilson, Wade T. Iams, Anita A. Turk, Praveen Vikas, Michael Cecchini, Sam Lubner, Priyadarshini Pathak, Kristen Spencer, Vadim S. Koshkin, Matthew K. Labriola, Catherine H. Marshall, Katy E. Beckermann, Marina N. Sharifi, Anthony C. Bejjani, Varsha Hotchandani, Samir Housri, Nadine Housri
Summary: Academics from National Cancer Institute-designated Comprehensive Cancer Centers in the United States share expert knowledge with oncologists across the country through an online Q&A platform, significantly impacting clinical practices, improving patient care, and providing a source of new knowledge and education in the field of oncology.
Article
Oncology
Hillary Stires, Igor Bado, Thelma Brown, Martha Carlson, Isaac S. Chan, Gloria V. Echeverria, Andrew J. Ewald, Bora Lim, Carla Lloyd, Julia Maues, Steffi Oesterreich, Robert N. Riter, Kelly Shanahan, Alana L. Welm, Josh Newby
Summary: Incorporating patient advocates into basic cancer research can enhance research intentionality, effective communication, and direct connections between researchers and those they aim to help. However, many cancer research scientists do not collaborate with patient advocates. Through hosting workshops and discussing findings at an international conference, we identified barriers and provided actionable steps to support researchers in working with patient advocates to improve cancer research and achieve our collective goal.
Article
Statistics & Probability
Juhee Lee, Peter F. Thall, Bora Lim, Pavlos Msaouel
Summary: A Bayesian method for personalized treatment selection is proposed, which takes into account the risk-benefit trade-off. A utility function varying with age is used to quantify the desirability of different outcome combinations, and a Bayesian nonparametric multivariate regression model is fitted to the trial data. The optimal treatment depends on the patient's age, with combination treatment preferable for patients 70 years or younger and single agent treatment preferable for patients older than 70.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS
(2022)
Article
Cell Biology
Yaohua Zhang, Chengcao Sun, Yajuan Li, Juan Qin, Kaushik Amancherla, Ying Jing, Qingsong Hu, Ke Liang, Zhao Zhang, Youqiong Ye, Lisa A. Huang, Tina K. Nguyen, Sergey D. Egranov, Zilong Zhao, Andrew Wu, Yutao Xi, Jun Yao, Mien-Chie Hung, George A. Calin, Jie Cheng, Bora Lim, Lorenz H. Lehmann, Joe-Elie Salem, Douglas B. Johnson, Michael A. Curran, Dihua Yu, Leng Han, Radbod Darabi, Liuqing Yang, Javid J. Moslehi, Chunru Lin
Summary: This study found that tumor-bearing mice treated with immune checkpoint inhibitors (ICIs) for cancer showed cardiovascular toxicities, including myocarditis and arrhythmia. Female mice were more susceptible to myocarditis. The down-regulation of MANF and HSPA5 in the heart tissue was associated with these cardiac effects.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Francois Richard, Maxim De Schepper, Marion Maetens, Sophia Leduc, Edoardo Isnaldi, Tatjana Geukens, Karen Van Baelen, Ha-Linh Nguyen, Peter Vermeulen, Steven Van Laere, Francois Bertucci, Naoto Ueno, Luc Dirix, Giuseppe Floris, Elia Biganzoli, Christine Desmedt
Summary: In this study, the genomic alterations in primary and metastatic tumor samples from patients with metastatic inflammatory breast cancer (IBC) and non-IBC were compared. Higher frequency of AURKA amplification was observed in IBC, which was associated with increased AURKA mRNA expression and worse prognosis. These findings should be further investigated considering the existence of AURKA inhibitors.
Article
Biochemistry & Molecular Biology
Mokryun L. Baek, Junegoo Lee, Katherine E. Pendleton, Mariah J. Berner, Emily B. Goff, Lin Tan, Sara A. Martinez, Iqbal Mahmud, Tao Wang, Matthew D. Meyer, Bora Lim, James P. Barrish, Weston Porter, Philip L. Lorenzi, Gloria V. Echeverria
Summary: It was found that mitochondrial oxidative phosphorylation (OXPHOS) was elevated in triple negative breast cancer (TNBC) cells surviving neoadjuvant chemotherapy (NACT). DNA-damaging agents increased mitochondrial fusion and OXPHOS, while taxanes decreased these effects. Inhibiting mitochondrial fusion and fission suppressed regrowth of residual tumor cells. These findings offer potential strategies to overcome mitochondrial adaptations in chemoresistant TNBC.
Article
Multidisciplinary Sciences
Daniel Wang, Caroline E. Porter, Bora Lim, Amanda Rosewell Shaw, Catherine S. Robertson, Mae L. Woods, Ya Xu, Greyson G. W. Biegert, Daisuke Morita, Tao Wang, Bambi J. Grilley, Helen Heslop, Malcolm K. Brenner, Masataka Suzuki
Summary: We have demonstrated the strong antitumor activity of a binary oncolytic/helper-dependent adenovirus (CAdVEC) that lyses tumor cells, expresses IL-12 and PD-L1 blocking antibody. Following successful preclinical studies, we treated four patients with an ultralow dose of CAdVEC, which resulted in significant tumor control and immune repolarization. The combination of CAdVEC with systemic immune checkpoint antibodies induced sustained antitumor responses.
Article
Oncology
Nour Abuhadra, Ryan Sun, Clinton Yam, Gaiane M. Rauch, Qingqing Ding, Bora Lim, Alastair M. Thompson, Elizabeth A. Mittendorf, Beatriz E. Adrada, Senthil Damodaran, Kiran Virani, Jason White, Elizabeth Ravenberg, Jia Sun, Jaihee Choi, Rosalind Candelaria, Banu Arun, Naoto T. Ueno, Lumarie Santiago, Sadia Saleem, Sausan Abouharb, Rashmi K. Murthy, Nuhad Ibrahim, Aysegul Sahin, Vicente Valero, William Fraser Symmans, Jennifer K. Litton, Debu Tripathy, Stacy Moulder, Lei Huo
Summary: In this study, clinicopathologic features, including sTILs, Ki-67, PD-L1, and androgen receptor, were evaluated in 408 early-stage TNBC patients. Integrating high Ki-67 (>35%) and high sTILs (≥20%) in a computed response score model predicted a pCR rate of 65%. This model has the potential to refine patient selection for neoadjuvant clinical trials evaluating de-escalation strategies.
Article
Oncology
Evan N. Cohen, Gitanjali Jayachandran, Hui Gao, Phillip Peabody, Heather B. McBride, Franklin D. Alvarez, Megumi Kai, Juhee Song, Yu Shen, Jie S. Willey, Bora Lim, Vicente Valero, Naoto T. Ueno, James M. Reuben
Summary: Circulating tumor cells (CTCs) are valuable indicators for managing metastatic breast cancer (MBC). Enrichment of CTCs based on size and deformability can capture a wider range of tumor cells, providing a complementary approach to tissue biopsy. A longitudinal study using a microcavity array showed that the shift from epithelial CTCs to those with a mesenchymal expression pattern is associated with worse clinical outcomes.
Article
Biochemistry & Molecular Biology
Xuemei Xie, Jangsoon Lee, Jon A. Fuson, Huey Liu, Toshiaki Iwase, Kyuson Yun, Cori Margain, Debu Tripathy, Naoto T. Ueno
Summary: In this study, RNAi screening and pathway analysis identified 135 potential kinase targets whose inhibition enhanced the antiproliferation effect of eribulin in TNBC cells. The PI3K/Akt/mTOR and MAPK/JNK pathways emerged as the top candidates. Combination of eribulin with copanlisib, everolimus, trametinib, and JNK-IN-8 produced strong synergistic antiproliferative effects, with the PI3K and mTOR inhibitors showing the most potent effects in vitro.
Article
Oncology
Hui Chen, Qingqing Ding, Laila Khazai, Li Zhao, Senthil Damodaran, Jennifer K. Litton, Gaiane M. Rauch, Clinton Yam, Jeffrey T. Chang, Sahil Seth, Bora Lim, Alastair M. Thompson, Elizabeth A. Mittendorf, Beatriz Adrada, Kiran Virani, Jason B. White, Elizabeth Ravenberg, Xingzhi Song, Rosalind Candelaria, Banu Arun, Naoto T. Ueno, Lumarie Santiago, Sadia Saleem, Sausan Abouharb, Rashmi K. Murthy, Nuhad Ibrahim, Mark J. Routbort, Aysegul Sahin, Vicente Valero, William Fraser Symmans, Debu Tripathy, Wei-Lien Wang, Stacy Moulder, Lei Huo
Summary: This study compared the differences in PTEN expression between pre- and post-treatment tumors in patients with triple-negative breast cancer (TNBC). It also explored the possibility of using next-generation sequencing (NGS) as an alternative to immunohistochemistry (IHC) to identify PTEN loss. The results showed that testing different specimens by IHC may generate different PTEN results in a small proportion of TNBC patients.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)